Template:Congestive heart failure: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 200: Line 200:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
ACC/AHA Guideline Recommendations:
2013 ACCF/AHA Guideline for the Management of Heart Failure
: [[2013 ACCF/AHA Guideline Definition of HF|Definitions of HFrEF and HFpEF]
: [[2013 ACCF/AHA Guideline Initial and Serial Evaluation of the HF Patient|Evaluation of the HF]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage A]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage B]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage C]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage D]]
: [[2013 ACCF/AHA Guideline The Hospitalized Patient|Hospitalized Patient]]
: [[2013 ACCF/AHA Guideline Surgical/Percutaneous/Transcather Interventional Treatments of HF]]
 
|- bgcolor="PaleTurquoise"
!
2009 ACC/AHA Guideline Recommendations:


: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patients]]
: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patients]]

Revision as of 13:47, 8 August 2013

Congestive heart failure Microchapters

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Endomyocardial biopsy

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Acute Pharmacotherapy
Chronic Pharmacotherapy:
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Antiarrhythmic Drugs
Nutritional Supplements
Omega-3-Fatty Acid
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

2013 ACCF/AHA Guideline for the Management of Heart Failure

[[2013 ACCF/AHA Guideline Definition of HF|Definitions of HFrEF and HFpEF]
Evaluation of the HF
Stage A
Stage B
Stage C
Stage D
Hospitalized Patient
2013 ACCF/AHA Guideline Surgical/Percutaneous/Transcather Interventional Treatments of HF

2009 ACC/AHA Guideline Recommendations:

Hospitalized Patients
Patients With a Prior MI
Sudden Cardiac Death Prevention
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF

Congestive heart failure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure

CDC on Congestive heart failure

Congestive heart failure in the news

Blogs on Congestive heart failure

Directions to Hospitals Treating Congestive heart failure

Risk calculators and risk factors for Congestive heart failure